Belgrade 2018 Meeting Highlights Registration Abstract Submission Exhibition Virtual Exhibition Hotel Information Satellite Programme Visa Letter Application

Transepithelial photorefractive keratectomy with collagen cross-linking for post LASIK ectasia and progressive keratoconus

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Cornea
Session Date/Time: Friday 09/02/2018 | 08:30-10:00
Paper Time: 09:33
Venue: Annex A

First Author: M.Bohac CROATIA
Co Author(s): M. Koncarevic  N. Gabric              

Abstract Details

Purpose:

To evaluate efficacy and safety of simultaneous ocular or corneal wavefront guided transepithelial photorefractive keratectomy (transPRK) and corneal collagen crosslinking (CXL) for progressive keratoconus and post LASIK ectasia.

Setting:

Specialty Eye Hospital Svjetlost Zagreb, School of Medicine University of Rijeka

Methods:

11 cases (10 patients) with progressive keratoconus and 4 cases (2 patients) with post LASIK ectasia were treated. Follow up was from 3 months up to 3 years. Corneal or ocular wavefront guided treatment was used depending on ablation plan and amount of tissue needed for excimer laser ablation. CXL with either 3 or 10 mW/cm2 lamp was used for irradiation.

Results:

Corrected distance visual acuity improved in all cases from 0.32±0.13 Snellen lines (range 0.1 to 0.6) to 0.74±0.20 (range 0.4 to 1.0). Kmax decreased from 50.95±5.21 D (range 43.1 to 58.2D) to 46.46±4.61 D (range 39.8 to 53.6D). There were no complications with corneal epithelialization which lasted in average for 5 days. Transient mild haze was noticed in all cases, 5 cases have permanent mild haze without influence on visual acuity. 2 cases (1 eye post LASIK ectasia and 1 eye keratoconus) are experiencing progressive flattening for up to 3 years after the treatment.

Conclusions:

Simultaneous transPRK and CXL is effective procedure for regularization of anterior surface and improvement of visual acuity in ectatic cornea. To prove its safety longer follow up with larger number of cases is needed.

Financial Disclosure:

None

Back to previous